Innovation in HTA: What is the additional value?
|
|
- Heather Cox
- 5 years ago
- Views:
Transcription
1 Innovation in HTA: What is the additional value? Stirling Bryan Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute School of Population & Public Health, UBC
2 My co-authors and funders: Craig Mitton Senior Scientist, Centre for Clinical Epidemiology & Evaluation, VCHRI Associate Professor, School of Population & Public Health, UBC Helen Lee Research Assistant, Centre for Clinical Epidemiology & Evaluation, VCHRI PhD candidate, University of Calgary Funding support Unrestricted grants from: -Vancouver Coastal Health Research Institute -Pfizer Canada
3 Everyone s talking innovation CHSPR 2009 Health Policy Conference Health Innovation for Patients and Populations McGill University Innovation Centre Utrecht University MSc in Drug Innovation Steve Jobs: Innovation distinguishes leaders from followers Woody Allen: If you re not failing every now and again, it s a sign you re not doing anything very innovative
4 Overview The issue: A lack of innovation in health care Definition: What is innovation? Demand side question: Is there an independent social value associated with innovation? Next steps and conclusions
5 Background Much discussion recently about 'innovation', or more precisely the lack of it, in the health care sector The concern: National guideline bodies (CDR, NICE) apply strict costeffectiveness criteria and so fail adequately to recognise the full benefits that come from innovation Sir David Cooksey: NICE appraisals do not operate in a way that is supportive of innovation... and therefore dissuade companies from investing in the UK (Cooksey, 2009) Sir Ian Kennedy: NICE should consider... agreeing a higher *cost-effectiveness] threshold in the case of innovation... and maintaining it for a fixed period (e.g. from 3-5 years) (Kennedy, 2009)
6 The drug itself has no side effects but the number of health economists needed to prove its value may cause dizziness and nausea
7 Background Much discussion recently about 'innovation', or more precisely the lack of it, in the health care sector The concern: National guideline bodies (CDR, NICE) apply strict costeffectiveness criteria and so fail adequately to recognise the full benefits that come from innovation Sir David Cooksey: NICE appraisals do not operate in a way that is supportive of innovation... and therefore dissuade companies from investing in the UK (Cooksey, 2009) Sir Ian Kennedy: NICE should consider... agreeing a higher *cost-effectiveness] threshold in the case of innovation... and maintaining it for a fixed period (e.g. from 3-5 years) (Kennedy, 2009)
8 Coverage decision-making criteria Clinical effectiveness Cost-effectiveness Acceptability Terminality Orphan drug Ministry priorities Innovativeness Wider societal considerations Etc. Dowie (2008)
9 (Dowie, 2008)
10 (Dowie, 2008)
11 To explore this issue, we need: A clear and agreed definition of innovation Clarity of the arguments: Demand side: Is there an independent (separable) social value associated with innovation? Supply side: What are the appropriate incentives to offer (e.g. patents, premium prices, other support for research) to ensure that socially valuable investment takes place?
12 What is innovation? Morgan, Lopert & Greyson (2008): Innovatory products must both meet unmet need and improve health outcomes. Kennedy (2009): Innovations must be new, must provide an improvement on existing products and must offer a step-change in terms of patient outcomes. Ferner, Hughes & Aronson (2010): An innovation offers treatment of a condition with no existing effective, or at least no completely satisfactory, intervention. Health Canada (2009): An innovation represents effective treatment, prevention or diagnosis of a disease or condition for which no drug (or medical device) is currently licensed in Canada.
13 Demand side considerations Is there an independent (separable) social value associated with innovation? Hypothetical example: Two groups of patients, A and B Equivalent in all important respects bar: Group A has no effective therapy currently Effective therapy is currently available for group B Extensive R&D delivers: An innovation for group A, NT a A new more effective therapy for group B, NT b
14 Patient Group A Patient Group B Full health Full health Health gain with NT a Health with NT a Health gain with NT b Health with NT b Original health Health gain With T b Current health Original health Additional QALYs for NT a : 1 Additional cost for NT a : $60,000 Additional QALYs for NT b : 1 Additional cost for NT b : $40,000
15 Example: Riluzole for ALS Prior to the launch of riluzole, patients with ALS had no effective therapy The development of riluzole was, therefore, an innovation It addressed an unmet need NICE CE estimate: approx. 40,000 per QALY NICE CE threshold: 20,000 per QALY But reimbursement guidance was positive The innovation premium is 20,000
16 Innovation, social value and incentives Demand side: Is there an independent (separable) social value associated with innovation (i.e. providing effective therapy for the first time)? Patients experiencing a serious condition for which no effective therapy is currently available Do they represent a disadvantaged group? Only if the answer is yes should we consider supply side incentives to promote innovations For example: a higher *cost-effectiveness] threshold in the case of innovation... (Kennedy, 2009) Others: patent enhancements, premium prices, innovation weights, other support for research
17 Thoughts? Questions?
ABHI Response to the Kennedy short study on Valuing Innovation
ABHI Response to the Kennedy short study on Valuing Innovation Introduction 1. The Association of British Healthcare Industries (ABHI) is the industry association for the UK medical technology sector.
More information13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer
13 December 2007 A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer Project Team Leela Barham Michelle Ng NERA Economic Consulting 15 Stratford Place London W1C 1BE United Kingdom Tel:
More informationHow can value be measured and assessed?
Dávid Dankó, PhD, MSc Corvinus University of Budapest Institute of Management david.danko at uni-corvinus.hu How can value be measured and assessed? ISPOR 5 th Asia-Pacific Conference, Taipei, 2 September
More informationEarly HTA to inform value driven market access and reimbursement planning
Early HTA to inform value driven market access and reimbursement planning Lotte MG Steuten, PhD Associate Prof. Health Technology & Services Research Program Director Health Sciences University of Twente,
More informationDecember Eucomed HTA Position Paper UK support from ABHI
December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing
More informationAndalusian Agency for Health Technology Assessment (AETSA)
Andalusian Agency for Health Technology Assessment (AETSA) Seville, 22 nd of July, 2016 Comments on the concept paper Facilitating the translation of advanced therapies to patients in Europe 1 Introduction
More informationHTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More informationMedical Research Council
Research Evaluation in the UK Ian Viney Medical Research Council Approaches used to understand and influence research impact 1. Collect comprehensive evidence of the progress, productivity and quality
More informationRational Use of New Medicines
Rational Use of New Medicines A Challenge for Health Policy Prof Ken Paterson EuroDURG/ISPE - Antwerp 2 December 2011 Increasing Pressures in all Health-Care Systems Population demography Aging population
More informationAnsgar Hebborn Hoffmann-La Roche, Basel, Switzerland
How Should a Societal Perspective in Economic Evaluation be Implemented? Ansgar Hebborn Hoffmann-La Roche, Basel, Switzerland ISPOR Amsterdam, 11 November 2014 The need to take a societal perspective How
More informationHealth Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities
Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Aleksandra Torbica, Carlo Federici, Rosanna Tarricone Centre for Research on Health and
More informationMedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)
MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry
More informationTranslational scientist competency profile
C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective
More informationTWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY
TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY A/Prof Tracy Merlin Adelaide Health Technology Assessment (AHTA) School of Population Health
More informationCompetition Regulation Innovation. Dr. Marisa Miraldo
Competition Regulation Innovation Dr. Marisa Miraldo m.miraldo@imperial.ac.uk Brussels, 27th October, 2016 Outline The R&D and innovation challenge Current incentives HTA assessment: (weak) incentive for
More informationOverview of Health Technology Assessment (HTA) from Asia Pacific Perspective
Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective Hong Li, PhD., MPH Group Director, Bristol-Myers Squibb Adjunct Associate Professor University of Cincinnati, USA; and DUKE-NUS
More informationCOMPONENT II CANDIDATE STUDY GUIDE PEDIATRIC DENTISTRY
COMPONENT II CANDIDATE STUDY GUIDE PEDIATRIC DENTISTRY Introduction The intent of this guide is to provide the candidate with an understanding of the format used for the Component II of the National Dental
More informationJustice Select Committee: Inquiry on EU Data Protection Framework Proposals
Justice Select Committee: Inquiry on EU Data Protection Framework Proposals Response by the Wellcome Trust KEY POINTS The Government must make the protection of research one of their priorities in negotiations
More informationStrategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use
Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use Rosmin Esmail MSc, CHE Director, Knowledge Translation Research, Analytics and Innovation Portfolio Alberta
More informationIntellectual Property
Intellectual Property Johnson & Johnson believes that the protection of intellectual property (IP) is essential to rewarding innovation and promoting medical advances. We are committed: to raising awareness
More informationCADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes
CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes Service Line: Health Technology Management Program Version: 1.0 Publication Date: September 2017 Report Length:
More informationNEWS RELEASE. Life sciences companies tout their expertise in India
For Immediate Release 2014MIT0016-000196 Feb. 19, 2014 NEWS RELEASE International Trade and Responsible for the Asia Pacific Strategy and Multiculturalism Life sciences companies tout their expertise in
More informationNHS Next Stage Review: Innovation
NHS Next Stage Review: Innovation January 2008 Introduction 1. The Academy of Medical Sciences welcomes the opportunity to contribute to the NHS Next Stage Review. In this short response we have focused
More informationBuilding quality into HTA and Coverage Decision- Making Processes: What are the features of good practice in HTA?
Workshop on Building quality into HTA and Coverage Decision- Making Processes: What are the features of good practice in HTA? 2 nd & 3 rd December 2013 Sheraton Heathrow Airport Hotel, UK PROGRAMME Organisers:
More informationCourse Outline and Syllabus for Students
Course Outline and Syllabus for Students Name: Monica Gautam Course Number: PHM321 Course Title: Selected Topics in Pharmaceutical Industry Course Description: This course is designed to expose students
More informationReflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation
Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process
More informationIP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?
IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationA Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data
External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on
More informationEXPLORATION DEVELOPMENT OPERATION CLOSURE
i ABOUT THE INFOGRAPHIC THE MINERAL DEVELOPMENT CYCLE This is an interactive infographic that highlights key findings regarding risks and opportunities for building public confidence through the mineral
More informationEPIDEMIOLOGY AND PUBLIC POLICY: THE ROLE OF THE INTERNATIONAL JOINT POLICY COMMITTEE OF THE SOCIETIES OF EPIDEMIOLOGY (IJPC-SE)
EPIDEMIOLOGY AND PUBLIC POLICY: THE ROLE OF THE INTERNATIONAL JOINT POLICY COMMITTEE OF THE SOCIETIES OF EPIDEMIOLOGY (IJPC-SE) MARK OREMUS, PHD COLIN L. SOSKOLNE, PHD CANADIAN SOCIETY FOR EPIDEMIOLOGY
More informationZayna Khayat, PhD., MaRS, Canada
Zayna Khayat, PhD., MaRS, Canada MaRSMission: improve public health & Improve health system performance, & drive the new health economy Senior Advisor, Director of EXCITE program pre-market health technology
More informationDigital Health and Introducing Innovative Technologies in the NHS
Digital Health and Introducing Innovative Technologies in the NHS 22 September 2015 NATIONAL INFORMATION BOARD techuk.org @techuk #techuk Digital Health and introducing innovative technologies in the NHS
More informationLundbeck s view on the EU IP systems
Lundbeck s view on the EU IP systems Forårsmøde IPR in the EU May 26 2011 H. Lundbeck A/S 1 Agenda The Innovative Pharmaceutical Industry and why IP is so important for Lundbeck Lundbeck s wish list for
More informationCentre for the Advancement of Health Innovations (CAHI)
Centre for the Advancement of Health Innovations (CAHI) Excellence in Clinical Innovation and Technology Evaluation Monday, April 16 th, 2012 The Old Mill Inn and Spa, Toronto ON Leslie Levin MB, MD, FRCP
More informationJOB DESCRIPTION. Department: Technical Length of contract: 3 years renewable. Reporting to: Chief of Party Direct reports: Numbers to be confirmed
JOB DESCRIPTION Job title: Technical Director and Malaria Specialist Location: Luanda Angola Department: Technical Length of contract: 3 years renewable Role type: Global Grade: 10 Travel involved: Frequent
More informationE5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,
More informationNew methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?
New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? Department director Øyvind Melien Reviews and HTA, Norwegian
More informationVirtual Clinical Trials: Challenges and Opportunities
Virtual Clinical Trials: Challenges and Opportunities November 28 29, 2018 National Academy of Sciences Building, Lecture Room 2101 Constitution Ave. NW, Washington, DC 20418 Background: The cost of bringing
More informationHealth Technology Assessment (HTA) Dr Hamid Ravaghi
Health Technology Assessment (HTA) Dr Hamid Ravaghi Why? What? How? 3 Why? New technologies Cost of new technologies Limited resources Ethical questions WHAT? Health Technology Instruments, equipment,
More informationChanging landscape - changing paradigms
IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute
More informationScottish Health and Life Sciences Innovation Workshop. The Industrial Strategy Challenge Fund
Scottish Health and Life Sciences Innovation Workshop The Industrial Strategy Challenge Fund Ian Campbell Innovate UK, Director of Health &Life Sciences Email:Ian.Campbell@innovateuk.gov.uk Twitter: @IanWCampbell
More informationSURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements
SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM 2014 Revision (v3) New ideas & Improvements Department of Surgery Evidence Decision Support Program Resource Tool Box Regional Clinical
More informationImproving Access to Innovative Health Technologies. Panel Discussion ISPOR Dubai - September 20, 2018
Improving Access to Innovative Health Technologies Panel Discussion ISPOR Dubai - September 20, 2018 Improving Access to Innovative Health Technologies Ansgar Hebborn, PhD F. Hoffmann-La Roche AG Basel,
More information2. Evidence themes and their importance along the development path
1. The issue On 12 th July 2017, MedCity, Digital Health.London and BSI hosted a Digital Health Technology and Evidence Stakeholder workshop. It brought together the key experts for the innovation development
More informationExploring Canada s early scientific advice: Global and Canadian context, CADTH and Health Canada perspectives. October 18, 2017
Exploring Canada s early scientific advice: Global and Canadian context, CADTH and Health Canada perspectives October 18, 2017 1 Today s par+cipants Panelist Panelist Panelist Panelist Don Husereau Health
More informationSecurity and Risk Assessment in GDPR: from policy to implementation
Global Data Privacy Security and Risk Assessment in GDPR: from policy to implementation Enisa Workshop Roma - February 8, 2018 Nicola Orlandi Head of Data Privacy Pharma Nicola Orlandi Nicola Orlandi is
More information(Fig.) JPMA Industry Vision 2025
2. JPMA Industry Vision 2025 Against the background of the changing environment surrounding the pharmaceutical industry and the future predictions *1, we prepared JPMA Industry Vision 2025 Bringing Innovation
More informationHealth Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI
Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI SAMED, Annual Conference, May 29 th 2014 From «Does
More informationStage 2: eligibility screening. Stage 3: prioritisation. Stage 4: selection
Digital therapy technology endorsement for IAPT project eligibility and prioritisation criteria NICE has been commissioned by NHS England to assess selected, digitally enabled therapies for depression
More informationSHTG primary submission process
Meeting date: 24 April 2014 Agenda item: 8 Paper number: SHTG 14-16 Title: Purpose: SHTG primary submission process FOR INFORMATION Background The purpose of this paper is to update SHTG members on developments
More informationHealthTech: What does it mean for compliance?
HealthTech: What does it mean for compliance? May 2018 Agenda 11:15 AM 11:30 AM Introduction Kathleen Meriwether, Americas Leader - Life Sciences Fraud Investigation & Dispute Services, EY 11:30 AM 12:15
More informationAlternatives to the patent system used to support R&D Efforts. James Love WIPO Expert Forum on International Technology Transfer February 17, 2015
Alternatives to the patent system used to support R&D Efforts James Love WIPO Expert Forum on International Technology Transfer February 17, 2015 Some conclusions {p1} The grant of exclusive rights to
More informationBefore I talk through the strategy itself, I want to tell you more about why
This presentation was given by Dr Annette Bramley, the Healthcare Technologies Theme leader. She thanked Professor Nelson and Professor Taylor for their presentations, and thanked everyone at the meeting
More informationEuropean Network for Health Technology Assessment (EUnetHTA) Joint Action 3
European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 Zoe Garrett, Senior Technical Adviser Lead WP7 National Implementation and Impact National Institute for Health and Care Excellence
More informationHealth Technology Assessment and the European Network for HTA
Health Technology Assessment and the European Network for HTA www.eunethta.eu Marcial Velasco Garrido, Technische Universität Berlin for the European Network for HTA, EUnetHTA Outline What is Health Technology
More informationReport of EPSRC Mathematical Sciences in Healthcare Scoping Meeting 15 SEPTEMBER 2014
Report of EPSRC Mathematical Sciences in Healthcare Scoping Meeting 15 SEPTEMBER 2014 Introduction and goals of the scoping meeting A small-scale scoping meeting was held on 15 th September 2014, to identify
More informationThe Health Information Future: Evolution and/or Intelligent Design?
The Health Information Future: Evolution and/or Intelligent Design? North American Association of Central Cancer Registries Conference Regina, Saskatchewan June 14, 2006 Steven Lewis Access Consulting
More informationIntegrated Scientific Advice Workshop: ISPOR Glasgow
Integrated Scientific Advice Workshop: ISPOR Glasgow Early Integrated Scientific Advice in Product Development: Get Real and Adapt to Accelerate Patient Access ICONplc.com Overview At today s patient-centered
More informationHTA, the roadmap from investment to disinvestment
HTA, the roadmap from investment to disinvestment Dr. Iñaki Gutiérrez-Ibarluzea Secretary of HTAi Osteba. Osasun Teknologien Ebaluazioaren Zerbitzua. Basque Office for HTA. Osasun Saila Ministry for Health
More informationKnowledge Translation: Where Are We? and Where Do We Go From Here?
Knowledge Translation: Where Are We? and Where Do We Go From Here? Ian D Graham, PhD, FCAHS PRAM- McGill University February 13, 2013 The Problem Knowledge Translation The Solution BUT What do we really
More informationDigital Health. Jiban Khuntia, PhD. Assistant Professor Business School University of Colorado Denver
Digital Health Jiban Khuntia, PhD Assistant Professor Business School University of Colorado Denver Digital Digital usually refers to something using digits, particularly binary digits. Examples: Digital
More informationReduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered?
3.3 Assessment: National health technology assessment unit 3.3.1 Introduction Health systems throughout the world are struggling with the challenge of how to manage health care delivery in resource-constrained
More informationMinistry of Justice: Call for Evidence on EU Data Protection Proposals
Ministry of Justice: Call for Evidence on EU Data Protection Proposals Response by the Wellcome Trust KEY POINTS It is essential that Article 83 and associated derogations are maintained as the Regulation
More informationEvidence for Effectiveness
Evidence for Effectiveness Developing a standards framework for digital health innovations Digitally empowering people to manage their health and care October 2018 The issue NHS England programmes Apps
More informationIssues in Emerging Health Technologies Bulletin Process
Issues in Emerging Health Technologies Bulletin Process Updated: April 2015 Version 1.0 REVISION HISTORY Periodically, this document will be revised as part of ongoing process improvement activities. The
More informationAdjusting your IWA for Global Perspectives
Adjusting your IWA for Global Perspectives Removing Stimulus Component: 1. When you use any of the articles from the Stimulus packet as evidence in your essay, you may keep this as evidence in the essay.
More informationAdaptation of HTA reports: an effective way to use limited resources?
Adaptation of HTA reports: an effective way to use limited resources? Iñaki Gutiérrez-Ibarluzea, Osteba, Basque Office for HTA. Ministry for Health, Basque Government Introducing the Basque Country Basque
More informationGlobal Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner
Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis
More informationExpectations around Impact in Horizon 2020
Expectations around Impact in Horizon 2020 Dr Ailidh Woodcock European Advisor, UK Research Office Ailidh.Woodcock@bbsrc.ac.uk 16 February 2017 University of Sheffield Agenda Start End Session 10:00 10:10
More informationDecision Determinants Guidance Document
Decision Determinants Guidance Document The Ontario Health Technology Advisory Committee (OHTAC) Decision-Making Process for the Development of Evidence-Based Recommendations Revised September 2010 Medical
More informationDirections for Health Research in BC
1 Our vision The best health for all British Columbians by excelling at research that we learn from and use to address priority health challenges. Content 01 A health research strategy for BC 03 The health
More informationWhere the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes
Where the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes Scientific innovation is at the heart of everything we do. Scientific innovation is at the heart of our business and
More informationTool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases In 2017 the multi-stakeholder initiative was set up to: Facilitate a shared understanding of the
More information'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint
'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint STOA workshop - European Parliament, 10 January 2019 Presented
More informationNew Technologies and Materials
New Technologies and Materials Daniel Delfosse BioTiNet, 2013-06-27 Topics 1. Introduction to orthopaedics (joint replacement) 2. Where are the problems to be solved? 3. What material or technology could
More informationHow The LifeTrain Principles Have Helped Me Develop Myself
How The LifeTrain Principles Have Helped Me Develop Myself Mark Calmiano LifeTrain Workshop Brussels 02.MAR.2015 Outline 2 Background To myself and to UCB Continuing Professional Development (CPD) At UCB
More informationOpportunities and Challenges in Pharmaceutical Sciences. Helen Gordon Chief Executive
Opportunities and Challenges in Pharmaceutical Sciences Helen Gordon Chief Executive Challenges we face Drivers for Change in Health Care... and science too Desire for high quality, safe services. The
More informationAgenda. Genesys Capital Partners. The Opportunity. Our Approach
MEDT Dinner Presentation September 28, 2005 Agenda Genesys Capital Partners The Opportunity Our Approach Genesys Capital Partners Genesys Capital Partners Successful Track Record Management experience
More informationNEW ZEALAND. Evaluation of the Public Good Science Fund An Overview.
NEW ZEALAND 1. General Policy Framework Key policy documents include: Blueprint for Change + Following the Blueprint. RS&T 2010. Building Tomorrow s Success. Setting Criteria for Government Investment.
More informationImplementation of Systems Medicine across Europe
THE CASyM ROADMAP Implementation of Systems Medicine across Europe A short roadmap guide 0 The road toward Systems Medicine A new paradigm for medical research and practice There has been a data generation
More informationRegulatory Science For Innovation
Regulatory Science For Innovation Fergal Donnelly European Commission Directorate-General for Research & Innovation Directorate 'Industrial Technologies' Unit 'Advanced Materials and Nanotechnology' The
More informationNational Coordinated Registry Network (CRN) Think-tank
National Coordinated Registry Network (CRN) Think-tank The Value of Real World Data for Innovation within FDA What can CRNs offer? Murray Sheldon, MD Associate Director for Technology and Innovation FDA/CDRH
More informationDriving Innovation. Connect and Catalyse. Medicines and Healthcare the Global perspective (+10 years) Zahid Latif
Connect and Catalyse Medicines and Healthcare the Global perspective (+10 years) Zahid Latif % GDP spent on health OECD countries spent nearly $3.5trn in 2005 ($4.6 trillion in 2008) on healthcare services
More informationG7 SCIENCE MINISTERS COMMUNIQUÉ
G7 SCIENCE MINISTERS COMMUNIQUÉ Turin, 27 28 September 28 th September 2017 Introduction We, the Science Ministers of Canada, France, Germany, Italy, Japan, the United Kingdom, the United States of America,
More informationNavigating the Healthcare Innovation Cycle
Navigating the Healthcare Innovation Cycle Introduction: CIMIT s 20 + years of experience in facilitating more than 600 projects is that innovation in Healthcare is a learnable, teachable process, which
More informationHTA in Norway- HTA - international challenges
NVTAG Symposium Drugs: An international perspective HTA in Norway- HTA - international challenges Berit Mørland, President HTAi Deputy director, The Norwegian Knowledge Centre for the Health Services My
More informationHAPPY JUNE! QUOTES. Biostatistics and Bioinformatics Department. Biostatistics and Bioinformatics. Inside This Issue
Biostatistics and Bioinformatics Biostatistics and Bioinformatics Department June 1, 018 HAPPY JUNE! QUOTES Inside This Issue Either write something worth reading or do something worth writing. Benjamin
More informationHOW THE PACE OF CHANGE AFFECTS THE OUTCOMES YOU GET:
HOW THE PACE OF CHANGE AFFECTS THE OUTCOMES YOU GET: T H E C A S E O F P H A R M A C E U T I C A L I N S U R A N C E I N C A N A D A, T H E U K A N D A U S T R A L I A CHEPA Seminar, April 2011 Katherine
More informationPatient safety and optimal performance:
Patient safety and optimal performance: a holistic framework for medical devices Michael Cheng Independent Patient Safety Advocate cheng12@sympatico.ca Canadian Agency for Drugs and Technologies in Health
More informationWhat s going on at the MRC
What s going on at the MRC Professor Sir John Savill Medical Research Council 04 October 2017 The Nurse Review Sir Paul Nurse The world is changing Population growth Changing demographics Migration Anthropocene
More informationStanding Committee on the Law of Patents
E SCP/24/4 ORIGINAL: ENGLISH DATE: JUNE 29, 2016 Standing Committee on the Law of Patents Twenty-Fourth Session Geneva, June 27 to 30, 2016 PROPOSAL BY THE AFRICAN GROUP FOR A WIPO WORK PROGRAM ON PATENTS
More informationWhy behavioural economics is essential for the success of the implementation of a wearable or health app. Behavioural Research Unit
Why behavioural economics is essential for the success of the implementation of a wearable or health app Behavioural Research Unit Speakers: Dr Lizzy Lubczanski Research Manager at Swiss Re s Behavioural
More informationPriorities for medical research in the UK
Priorities for medical research in the UK Sir Leszek Borysiewicz Medical Research Council The Foundation for Science and Technology, 20 May 2009 MRC mission Encourage and support high-quality research
More informationSession VI Knowledge Transfer and Open Access
Y IS OUR ERA Session VI Knowledge Transfer and Open Access Knowledge circulation: Knowledge Transfer and Open Access knowledge transfer OpenAIRE free online access dissemination knowledge circulation
More informationGlobal Transcatheter Aortic Valve Replacement (TAVR) Market: Trends & Opportunities [ ]
Global Transcatheter Aortic Valve Replacement (TAVR) Market: Trends & Opportunities [2013-18] Scope of the Report The report titled Transcatheter Aortic Valve Replacement Market (TAVR): Trends and Opportunities
More informationOverview: Social sciences and AMR. Professor Ian Donald Department of Psychological Sciences Institute of Psychology, Health and Society
Overview: Social sciences and AMR Professor Ian Donald Department of Psychological Sciences Institute of Psychology, Health and Society Overview Background of recognition and support Cross Council Initiative
More informationMEASURING R&D IMPACT: BETWEEN REALITY AND EXPECTATIONS DR. ABDUL SATTAR AL-TAIE QNRF EXECUTIVE DIRECTOR NOVEMBER
MEASURING R&D IMPACT: BETWEEN REALITY AND EXPECTATIONS DR. ABDUL SATTAR AL-TAIE QNRF EXECUTIVE DIRECTOR NOVEMBER 8-2015 WHAT IS RESEARCH IMPACT? The Oxford English Dictionary defines impact as Marked effect
More informationSMA Europe Code of Practice on Relationships with the Pharmaceutical Industry
Introduction SMA Europe Code of Practice on Relationships with the Pharmaceutical Industry SMA Europe is an umbrella body of national Spinal Muscular Atrophy patient representative and research organisations
More informationConvergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA
EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,
More information